Internship

Summer 2024 – X-Ray Crystallography Drug Discovery Internship

Posted on 10/11/2023

Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Biotechnology
Healthcare

Company Historically Provides H1B Sponsorship

Princeton, NJ, USA

Required Skills
Communications

You match the following Bristol Myers Squibb's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Completed at least two years of undergraduate coursework at a university
  • Strong analytical and organizational skills
  • Excellent communication and collaboration skills
  • Preferred majors: Chemistry, Biochemistry, Biophysics, Biology
  • Basic lab technique skills

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are then sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet the same quality and safety standards. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, as well as its commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by providing access to effective and affordable healthcare solutions.

Company Size

10,001+

Company Stage

IPO

Total Funding

$33.7B

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • BMS's partnership with Medidata streamlines clinical trials, improving efficiency and outcomes.
  • Cost-cutting initiatives aim for $2 billion savings, potentially boosting financial health.
  • Nanoneedle technology in AAV manufacturing could enhance product quality and efficacy.

What critics are saying

  • Significant workforce reductions may impact employee morale and productivity.
  • Competition in oncology from biotech firms like ArsenalBio poses a market challenge.
  • Financial pressure from cost-cutting may affect R&D investment and innovation.

What makes Bristol Myers Squibb unique

  • BMS focuses on innovative cancer treatments, including T cell therapies for solid tumors.
  • The company is committed to global health, addressing diseases like sickle cell in Africa.
  • BMS integrates digital trial management tools to enhance clinical research and patient outcomes.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

PR Newswire
Feb 12th, 2025
Nanomosaic Announced Release Of Joint White Paper With Bms Investigating Nanoneedle Technology To Improve Aav Manufacturing Process And Product Quality

WALTHAM, Mass., Feb. 12, 2025 /PRNewswire/ -- Nanomosaic, a leader in multiplex, multi-omic marker analysis, today announced the publication of a scientific white paper detailing a study conducted with Bristol Myers Squibb (BMS). The paper explores the potential of the nanoneedle technology as an innovative tool for enhancing the depth and breadth of insights into AAV (adeno-associated virus) manufacturing processes and product quality. During AAV production, natural variations in the viral genome lead to the formation of subpopulations within a single batch. These variations can negatively impact the efficiency of the vector, potentially compromising therapeutic efficacy or causing unintended side effects due to suboptimal AAV subpopulations. To mitigate these risks, AAV developers and manufacturers implement strategies to selectively enrich preparations with particles containing a complete transgene capable of delivering the desired therapeutic effect

ROI-NJ
Feb 6th, 2025
Bristol Myers Launches New Round Of Cost Cutting Initiatives

Bristol Myers Squibb is planning another round of cost cutting initiatives.On Thursday, the Princeton-based firm said it plans to find $2 billion in additional savings over the next three years, on top of the $1.5 billion in cuts it announced in April 2024. The company has been looking to improve its efficiency by reducing clinical trial expenses, rationalizing its operating footprint and reducing its head count.The new reductions will come in two major categories: cuts to the workforce, including contract positions, open roles and attrition. The second set is made up of operating costs such as marketing spending on older drugs, clinical trial operations and supply chain items like manufacturing facilities and outside contractors.BMS’ latest workforce reduction affects 67 employees in Lawrence Township, according to a New Jersey Worker Adjustment and Retraining Notification (WARN) notice. The notice lists several effective dates for the cuts stretching into December.BMS is expected to dismiss more than 2,000 employees in total as part of the overhaul. Last year alone, BMS filed six WARN notices affecting a total of 1,329 staffers in Lawrenceville, which hosts the company’s sprawling corporate headquarters and a Princeton Pike facility for commercial and late-stage development functions

Insider Monkey
Jan 21st, 2025
Why Is Bristol-Myers Squibb Company (BMY) Among the Best High-Yield Dividend Stocks to Invest In?

Why is Bristol-Myers Squibb Company (BMY) among the Best High-Yield Dividend Stocks to Invest In?

Business Wire
Jan 20th, 2025
Be Bio Announces Closing of $92M Series C Financing and Completes Transition to a Multi-Program, Clinical Stage Company

Be Biopharma, Inc. (“Be Bio” or “the Company”), a leader in B Cell Medicines (BCMs), today announced the closing of its $92M Series C financing. The r

PR Newswire
Jan 17th, 2025
Bristol Myers Squibb Foundation, Texas Children'S Global Hope, Baylor College Of Medicine Global Health Launch Program To Combat Sickle Cell Disease In Sub-Saharan Africa

New Initiative in Partnership with Africa Centers for Disease Control (Africa CDC) and Local Ministries of Health Builds on Decades of Capacity Building to combat HIV and Pediatric CancerHOUSTON, Jan. 17, 2025 /PRNewswire/ -- Texas Children's Global HOPE and Baylor College of Medicine Global Health, with support from the Bristol Myers Squibb Foundation, an independent charitable organization, announced the next front in their joint efforts to dramatically improve children's health in Sub-Saharan Africa with the launch of a groundbreaking program to address one of the most urgent threats facing the region: sickle cell disease (SCD)

INACTIVE